Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.
This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isola...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4081561?pdf=render |
| _version_ | 1818286559570427904 |
|---|---|
| author | Michael A Pfaller David R Andes Daniel J Diekema David L Horn Annette C Reboli Coleman Rotstein Billy Franks Nkechi E Azie |
| author_facet | Michael A Pfaller David R Andes Daniel J Diekema David L Horn Annette C Reboli Coleman Rotstein Billy Franks Nkechi E Azie |
| author_sort | Michael A Pfaller |
| collection | DOAJ |
| description | This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C. glabrata (46.4%), C. parapsilosis (24.7%), C. tropicalis (13.9%), C. krusei (5.5%), C. lusitaniae (1.6%), C. dubliniensis (1.5%) and C. guilliermondii (0.4%); 111 infections involved two or more species of Candida (4.4%). Non-albicans species accounted for more than 50% of all cases of invasive candidiasis in 15 of the 24 sites (62.5%) that contributed more than one case to the survey. Among solid organ transplant recipients, patients with non-transplant surgery, and patients with solid tumors, the most prevalent non-albicans species was C. glabrata at 63.7%, 48.0%, and 53.8%, respectively. In 1,883 patients receiving antifungal therapy on day 3, fluconazole (30.5%) and echinocandins (47.5%) were the most frequently administered monotherapies. Among the 15 reported species, 90-day survival was highest for patients infected with either C. parapsilosis (70.7%) or C. lusitaniae (74.5%) and lowest for patients infected with an unknown species (46.7%) or two or more species (53.2%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in North America. The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy. |
| first_indexed | 2024-12-13T01:26:31Z |
| format | Article |
| id | doaj.art-9d8ac734f4914d75b44270eb64b44921 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T01:26:31Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9d8ac734f4914d75b44270eb64b449212022-12-22T00:04:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0197e10151010.1371/journal.pone.0101510Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.Michael A PfallerDavid R AndesDaniel J DiekemaDavid L HornAnnette C ReboliColeman RotsteinBilly FranksNkechi E AzieThis analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isolates were identified. The identified species were C. glabrata (46.4%), C. parapsilosis (24.7%), C. tropicalis (13.9%), C. krusei (5.5%), C. lusitaniae (1.6%), C. dubliniensis (1.5%) and C. guilliermondii (0.4%); 111 infections involved two or more species of Candida (4.4%). Non-albicans species accounted for more than 50% of all cases of invasive candidiasis in 15 of the 24 sites (62.5%) that contributed more than one case to the survey. Among solid organ transplant recipients, patients with non-transplant surgery, and patients with solid tumors, the most prevalent non-albicans species was C. glabrata at 63.7%, 48.0%, and 53.8%, respectively. In 1,883 patients receiving antifungal therapy on day 3, fluconazole (30.5%) and echinocandins (47.5%) were the most frequently administered monotherapies. Among the 15 reported species, 90-day survival was highest for patients infected with either C. parapsilosis (70.7%) or C. lusitaniae (74.5%) and lowest for patients infected with an unknown species (46.7%) or two or more species (53.2%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in North America. The variability in species distribution in these centers underscores the importance of local epidemiology in guiding the selection of antifungal therapy.http://europepmc.org/articles/PMC4081561?pdf=render |
| spellingShingle | Michael A Pfaller David R Andes Daniel J Diekema David L Horn Annette C Reboli Coleman Rotstein Billy Franks Nkechi E Azie Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS ONE |
| title | Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. |
| title_full | Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. |
| title_fullStr | Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. |
| title_full_unstemmed | Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. |
| title_short | Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. |
| title_sort | epidemiology and outcomes of invasive candidiasis due to non albicans species of candida in 2 496 patients data from the prospective antifungal therapy path registry 2004 2008 |
| url | http://europepmc.org/articles/PMC4081561?pdf=render |
| work_keys_str_mv | AT michaelapfaller epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT davidrandes epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT danieljdiekema epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT davidlhorn epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT annettecreboli epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT colemanrotstein epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT billyfranks epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 AT nkechieazie epidemiologyandoutcomesofinvasivecandidiasisduetononalbicansspeciesofcandidain2496patientsdatafromtheprospectiveantifungaltherapypathregistry20042008 |